title: Treatment of vitamin D depletion after Roux-en-Y gastric bypass: a randomized prospective clinical trial.
abstract: BACKGROUND
  A high prevalence (60%) of vitamin D (VitD) depletion, defined as a serum 25-hydroxyvitamin D level of < or =20 ng/mL, is present in preoperative morbidly obese patients. Despite daily supplementation with 800 IU VitD and 1500 mg calcium after Roux-en-Y gastric bypass (RYGB), VitD depletion persists in almost one half (44%) of patients. However, the optimal management of VitD depletion after RYGB and the potential benefits of such treatment are currently unknown.
  
  
  METHODS
  A total of 60 VitD-depleted morbidly obese women were randomly assigned to receive 50,000 IU of VitD weekly after RYGB (group 1; n = 30) or no additional VitD after RYGB (group 2; n = 30). All patients received a daily supplement of 800 IU VitD and 1500 mg calcium. The serum calcium, parathyroid hormone, 25-hydroxyvitamin D, bone-specific alkaline phosphatase, urinary N-telopeptide, and bone mineral density were measured preoperatively and 1 year after RYGB. Questionnaires were used to assess other potential sources of VitD, including sunlight exposure and ingestion of VitD-containing foods/liquids.
  
  
  RESULTS
  At 1 year after RYGB, VitD depletion and mean 25-hydroxyvitamin D level had improved significantly in group 1 (14% and 37.8 ng/mL, respectively) compared with the values in group 2 (85% and 15.2 ng/mL, respectively; P <.001 for both). A significant 33% retardation in hip bone mineral density decline (P = .043) and a significantly greater resolution of hypertension was seen in group 1 (75% versus 32%; P = .029). No significant adverse effects were encountered from pharmacologic VitD therapy.
  
  
  CONCLUSIONS
  The results of our study have shown that 50,000 IU of VitD weekly after RYGB safely corrects VitD depletion in most women, attenuates cortical bone loss, and improves resolution of hypertension.
authors.affiliation: Division of General Surgery, Henry Ford Hospital, Detroit, Michigan, USA.
authors.forename: Arthur M
authors.initials: AM
authors.lastname: Carlin
authors.forename: D Sudhaker
authors.initials: DS
authors.lastname: Rao
authors.forename: Kelli M
authors.initials: KM
authors.lastname: Yager
authors.forename: Nayana J
authors.initials: NJ
authors.lastname: Parikh
authors.forename: Alissa
authors.initials: A
authors.lastname: Kapke
mesh_terms: D000328:Adult; D015519:Bone Density; D019587:Dietary Supplements; D005260:Female; D015390:Gastric Bypass; D006801:Humans; D008875:Middle Aged; D009767:Obesity, Morbid / Q000150:complications / Q000378:metabolism / Q000601:surgery*; D010281:Parathyroid Hormone / Q000097:blood; D012307:Risk Factors; D016896:Treatment Outcome; D014807:Vitamin D / Q000008:administration & dosage* / Q000031:analogs & derivatives / Q000097:blood; D014808:Vitamin D Deficiency / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D014815:Vitamins / Q000008:administration & dosage*; D015431:Weight Loss
chemical_list: D010281:Parathyroid Hormone; D014815:Vitamins; D014807:Vitamin D; C104450:25-hydroxyvitamin D